SURPASS-CVOT post hoc: broader cardiorenal outcomes favor tirzepatide vs dulaglutide
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.